Skip to main
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 25%
Buy 13%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra Inc. is poised for significant financial growth, with expectations for mid-teens revenue growth and potential acceleration into the high-teens by 2026, driven by new product launches and reduced regulatory headwinds, particularly in the neurovascular segment. The company's ability to increase gross and operating margins alongside projected EPS growth that outpaces revenue growth further enhances its financial outlook. Additionally, Penumbra's position as a market leader with robust innovation in the thrombectomy space positions it favorably for continued market penetration and share capture from competitors, reinforcing its attractiveness as an investment opportunity.

Bears say

Penumbra Inc faces significant risks that may hinder its future growth, such as increased competition in the mechanical thrombectomy market and potential delays in new product approvals. Additionally, challenges related to reimbursement changes could place pressure on the company's revenue stream and limit physician interest in its devices. Furthermore, if clinical trial outcomes do not demonstrate a clear advantage for Penumbra's technologies compared to existing alternatives, the company's ability to capture market share and grow its business may be severely constrained.

Penumbra (PEN) has been analyzed by 16 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Buy based on their latest research and market trends.

According to 16 analysts, Penumbra (PEN) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $359.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $359.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.